Recombinant Human LAIR2 His-tag Avi-tag Protein, CF

When Bovine Collagen I is coated at 10 µg/mL, 100 μL/well,Recombinant Human LAIR2 His-tag Avi-tag (Catalog # AVI2665) binds with anED50 of 0.75-6 ng/mL.

2 μg/lane of Biotinylated Recombinant Human LAIR2 His-Tag Avi-tag (Catalog # AVI2665)was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditionsand visualized by Coomassie® Bluestaining, showing bands at 20-28 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human LAIR2 His-tag Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Bovine Collagen I is coated at 10 µg/mL, 100 μL/well, Recombinant Human LAIR2 His-tag Avi-tag (Catalog # AVI2665) binds with an ED₅₀ of 0.75-6 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human LAIR2 protein
  

  Human LAIR2 (Glu23-Pro152) Accession # Q6ISS4-1	HHHHHH	Avi-tag
  N-terminus		C-terminus

• Accession #: Q6ISS4-1
• N-terminal Sequence: No results obtained: Gln22 inferred from enzymatic pyroglutamate treatment revealing Glu23
• Structure / Form: Biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 17 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 20-28 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human LAIR2 His-tag Avi-tag Protein, CF

• CD306 antigen
• CD306
• CD306leukocyte-associated Ig-like receptor-2
• LAIR2
• LAIR-2
• leukocyte-associated Ig-like receptor 2
• leukocyte-associated immunoglobulin-like receptor 2
• MGC71634

Background

LAIR2 (leukocyte-associated Ig-like receptor-2; CD306) is a secreted, 131 amino acid (aa) protein that contains one Ig-like C2 type domain, making it a member of the Ig superfamily. When compared to LAIR1, its transmembrane counterpart, LAIR2 shares 83% aa identity across the signal sequence and extracellular domains (1-3). Although one is secreted and the other is membrane-bound, the two LAIR proteins are thought to have arisen from a common gene ancestor and appear to share similar adhesion profiles. This suggests that LAIR2 may compete with LAIR1 for ligand binding (3, 4). A 114 aa alternate splice form of LAIR-2 is truncated at the C-terminus, but retains the entire Ig domain (1-3). The expression profile of these splice forms, and the presence of orthologs in other species, have not been reported. LAIR2 is a soluble collagen-receptor, and it can be detected in the synovial fluid of rheumatoid arthritis patients, urine of pregnant women, and as well as primary cells (5, 6). In vitro studies have demonstrated LAIR2 can compete with LAIR1 for the same collagen binding site and suggesting LAIR2 may play an important role in immune cell activation (5, 6). LAIR2 can interact with complement component 1q (C1q) and mannose-binding lectin (MBL) and act as a complement inhibitor for the treatment and prevention of antibody-mediated allograft rejection and antibody-mediated clinical conditions (7).

1. Meyaard, L. (2003) J. Biol. Regul. Homeost. Agents 17:330.
2. Meyaard, L. et al. (1999) J. Immunol. 162:5800.
3. Meyaard, L. et al. (1997) Immunity 7:283.
4. Xu, X.G. et al. (2005) Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 21:553.
5. Lebbink, R.J. et al. (2008) J. Immunol. 180:1662.
6. Olde Nordkamp, M.J. et al. (2011) Arthritis Rheum. 63:3749.
7. Olde Nordkamp, M.J. et al. (2014) J. Innate Immun. 6:284.

Bioinformatics

• Uniprot:
  • Q6ISS4-1()